» Articles » PMID: 16142473

Fugetaxis: Active Movement of Leukocytes Away from a Chemokinetic Agent

Overview
Specialty General Medicine
Date 2005 Sep 6
PMID 16142473
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Chemotaxis or active movement of leukocytes toward a stimulus has been shown to occur in response to chemokinetic agents including members of the recently identified superfamily of proteins called chemokines. Leukocyte chemotaxis is thought to play a central role in a wide range of physiological and pathological processes including the homing of immune cells to lymph nodes and the accumulation of these cells at sites of tissue injury and pathogen or antigen challenge. We have recently identified a novel biological mechanism, which we term fugetaxis (fugere, to flee from; taxis, movement) or chemorepulsion, which describes the active movement of leukocytes away from chemokinetic agents including the chemokine, stromal cell derived factor-1, and the HIV-1 envelope protein, gp120. In this article, we review the evidence that supports the observation that leukocyte fugetaxis occurs in vitro and in vivo and suggestions that this novel mechanism can be exploited to modulate the immune response. We propose that leukocyte fugetaxis plays a critical role in both physiological and pathological processes in which leukocytes are either excluded or actively repelled from specific sites in vivo including thymic emigration, the establishment of immune privileged sites and immune evasion by viruses and cancer. We believe that current data support the thesis that a greater understanding of leukocyte fugetaxis will lead to the development of novel therapeutic approaches for a wide range of human diseases.

Citing Articles

Unraveling impact and potential mechanisms of baseline pain on efficacy of immunotherapy in lung cancer patients: a retrospective and bioinformatic analysis.

Zhang Z, Zhao W, Lv C, Wu Z, Liu W, Chang X Front Immunol. 2024; 15:1456150.

PMID: 39654896 PMC: 11625792. DOI: 10.3389/fimmu.2024.1456150.


assessment of CAR macrophages activity against SARS-CoV-2 infection.

Amoddeo A Heliyon. 2024; 10(21):e39689.

PMID: 39524874 PMC: 11550025. DOI: 10.1016/j.heliyon.2024.e39689.


A mathematical model and numerical simulation for SARS-CoV-2 dynamics.

Amoddeo A Sci Rep. 2023; 13(1):4575.

PMID: 36941368 PMC: 10027279. DOI: 10.1038/s41598-023-31733-2.


A meta-analysis indicates that the regulation of cell motility is a non-intrinsic function of chemoattractant receptors that is governed independently of directional sensing.

Rodriguez-Fernandez J, Criado-Garcia O Front Immunol. 2022; 13:1001086.

PMID: 36341452 PMC: 9630654. DOI: 10.3389/fimmu.2022.1001086.


Semaphorin 3A in the Immune System: Twenty Years of Study.

Kiseleva E, Rutto K Biochemistry (Mosc). 2022; 87(7):640-657.

PMID: 36154881 PMC: 9282903. DOI: 10.1134/S0006297922070069.


References
1.
Rempel S, Dudas S, Ge S, Gutierrez J . Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Clin Cancer Res. 2000; 6(1):102-11. View

2.
Bielenberg D, Hida Y, Shimizu A, Kaipainen A, Kreuter M, Kim C . Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. J Clin Invest. 2004; 114(9):1260-71. PMC: 524226. DOI: 10.1172/JCI21378. View

3.
Tashiro K, Nakano T, Honjo T . Signal sequence trap. Expression cloning method for secreted proteins and type 1 membrane proteins. Methods Mol Biol. 1997; 69:203-19. DOI: 10.1385/0-89603-383-x:203. View

4.
Kenakin T . Principles: receptor theory in pharmacology. Trends Pharmacol Sci. 2004; 25(4):186-92. DOI: 10.1016/j.tips.2004.02.012. View

5.
Smyth M, Godfrey D, Trapani J . A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol. 2001; 2(4):293-9. DOI: 10.1038/86297. View